Sonidegib

Sonidegib (INN) or erismodegib (USAN), also known as LDE225, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. It has been investigated as a potential treatment for:

• Pancreatic cancer
• Breast cancer
• Basal cell carcinoma of the skin
• Small cell lung cancer
• Medulloblastoma
• Advanced solid tumours (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)
• Acute leukaemia
• Chronic myeloid leukaemia
• Myelofibrosis and essential thrombocythaemia

It has demonstrated significant efficacy against melanoma in vitro and in vivo. It also demonstrated efficacy in a mouse model of pancreatic cancer.

Reference list

The article on Sonidegib is a stub. YOU can help Wikimd by expanding it!

Medication resources

WikiMD is a sponsored by W8MD Weight loss, sleep and medical aesthetics.

Learn more

• Dailymed label info
• Scientific articles

edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Sonidegib or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.